A phase 2 study of mirdametinib and vinblastine for newly diagnosed or previously untreated patients with pediatric low-grade glioma and activation of the MAPK pathway
A phase 2 study of mirdametinib and vinblastine for newly diagnosed or previously untreated patients with pediatric low-grade glioma and activation of the MAPK pathway
Mirdametinib 和长春花碱治疗新诊断或既往未经治疗的儿童低级别胶质瘤患者和 MAPK 通路激活的 2 期研究
批准号：
465505
负责人：
Perreault Sebastien
金额：
$33.77万
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
已结题
起止时间：
2022-03-01 至 2023-08-01
关键词：
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in children. Whereas, some patients can be cured with surgery alone, a significant number will need complimentary treatments since location such as optic pathway or brainstem precludes
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Phase 2 study of Trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathwa
-
批准号：401189
-
项目类别：Operating Grants
-
资助金额：$41.8万
-
财政年份：2019
-
负责人：Perreault Sebastien
-
依托单位：
海外基金
